The FDA cleared a second arm for enrollment in the trial after one NSCLC patient demonstrated a complete response to the non-boosted therapy.

Researchers hope to undertake clinical studies in multiple cancers, including ovarian cancer, glioblastoma, and others.

A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage immunotherapy company developing first-in-class logic-gated therapies for ...

Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing processReceived FDA ...

Immunocore reports fourth quarter and full year 2025 financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q4 net sales of $104.5 million and $400.0 million for full year 2025; ...

Kidney transplantation remains the treatment of choice for end-stage renal disease; however, long-term graft survival continues to be limited by alloimmune ...

The central question is no longer whether we can innovate, but whether innovation can truly reach patients in time.

The AACR 2026 conference will be held from April 17-22, 2026. The AACR plans to publish the abstract titles on March 17, 2026 at 4:30 pm EST, the abstracts on April 17, 2026 at 3:00 pm EST, and the ...

The first gene therapies approved to treat sickle cell disease in December 2023 are struggling on the market. But there are glimpses of forward momentum as Vertex and Genetix Bio provide updates.

A Japanese study of more than 7,400 patients has identified a genetic mismatch that sharply increases the risk of severe acute graft-versus-host disease (GVHD) following umbilical cord blood ...

Umbilical cord blood transplantation has transformed the treatment options for patients with blood cancers and other life-threatening hematologic disorders, particularly when matched donors are ...

After losing the only two stem cell donor matches for his son, who has a rare blood disorder, Juan Uribe posted a plea to ...